GLP1R and early-onset autosomal dominant Alzheimer disease: Whilst it is promising that the administration of a GLP-1 RA was associated with a reduction in inflammatory biomarkers, many have called for cognitive functioning to be the pivotal assessment of a drug’s efficacy in Alzheimer’s disease trials [47].